<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1274">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553705</url>
  </required_header>
  <id_info>
    <org_study_id>TQ/Omega-3 on COVID-19</org_study_id>
    <secondary_id>DOI: 10.31219/osf.io/u56fc</secondary_id>
    <nct_id>NCT04553705</nct_id>
  </id_info>
  <brief_title>Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)</brief_title>
  <official_title>Impact of Different Treatment Modalities on Immunity Against COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternity and Children Hospital, Makkah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of Pharmacy,Department of Pharmacy Practice,University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first version of this preprint article is registered on the 4th of May 2020 under the
      digital object identifier of:10.31219/osf.io/u56fc.

      COVID-19 infections virus spread worldwide and impact many countries with sever economical
      sequences. The effective antiviral medication or vaccination for the virus is unavailable
      until the present date and it takes months or years to discover the effective treatment or
      test the efficacy of the discovered treatment.

      Based on these facts, the human immune system against the virus may have an effective role to
      regulate the infection and reduce the mortality rate among the infected patients. This
      proposed research article aims to explore the available medication/ natural supplementation
      to boost the immunity system of the patients against COVID-19 infections and reduce the
      mortality rate among infected patients. Methods: a proposed clinical trial will be carried
      out to investigate the effect of the different treatment modalities on the human immune
      system against COVID-19 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Natural supplementations have many reported effects on the human health ranged from immunity
      boosting to effective antiviral effect. Omeg-3 as an example affect the human health by many
      mechanisms e.g. Anti-oxidant, immunity boosting agent. Moreover, Omega-3 exerts an antiviral
      effect on Flu virus by inhibiting influenza virus replication 1. On the other hand, black
      seed supplementation exerts a chelation effect on sickle cell anemia patients and inhibits
      Human Heme Metabolism 2. Moreover, black seed exerts an antiviral effect on the replication
      of old coronavirus and the expression of (TRP-genes) family 3. In addition, Omega-3 regulates
      the human immunity against bacterial and viral infections 4. During the past years, many
      natural sources exerts an antimalarial effect with perfect reported results 5.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 20, 2020</start_date>
  <completion_date type="Anticipated">December 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement</measure>
    <time_frame>30 Days</time_frame>
    <description>Time to Clinical recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery rate from positive to negative swaps</measure>
    <time_frame>14 Days</time_frame>
    <description>Percentage of patients returned to negative swaps of COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fever to normal temperature in days</measure>
    <time_frame>15 Days</time_frame>
    <description>Number of days for fever remission T=37.5°C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission of lung inflammation in CT or X-ray</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of days to report lungs recovery in chest X ray or CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>10 Days</time_frame>
    <description>Number of days for hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(PCR levels) polymerase chain reaction assay levels</measure>
    <time_frame>10 Days</time_frame>
    <description>Change of (PCR levels) &gt; 50% in comparison with PCR levels at the admission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory indexes</measure>
    <time_frame>10 Days</time_frame>
    <description>P O2/Fi O2 which reflects patients' oxygen saturation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein mg/L</measure>
    <time_frame>25 Days</time_frame>
    <description>C-reactive protein milligrams per deciliter correlated with inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Ferritin ng/ml</measure>
    <time_frame>25 Days</time_frame>
    <description>Serum Ferritin Nanograms per milliliter correlated with iron overload and illness severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactic acid dehydrogenase U/L</measure>
    <time_frame>25 Days</time_frame>
    <description>Lactic acid dehydrogenase unit per litter correlated with illness severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>leukocytes count μl</measure>
    <time_frame>30 Days</time_frame>
    <description>leukocytes in microliter correlated with mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid profile [LDL, HDL, Total cholesterol ]</measure>
    <time_frame>14 Days</time_frame>
    <description>Mg/dl correlated with lipid peroxidation that linked to oxidative stress</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total plasma antioxidant capacity</measure>
    <time_frame>14 Days</time_frame>
    <description>Evaluate the antioxidant response against the free radicals produced in COVID-19 infection measured by ELISA</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <condition>Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>Omega-3/thymoquinone supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA &amp; 200-300mg DHA) (3% thymoquinone) per day for one month.
In addition to the standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3/thymoquinone / Indian Costus supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA &amp; 200-300mg DHA), (3% thymoquinone),(Indian Costus) per day for one month.
In addition to the standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3/thymoquinone / Quinine pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA &amp; 200-300mg DHA), (3% thymoquinone),(1g Quinine) per day for one month.
In addition to the standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3/thymoquinone / Anise seed capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA &amp; 200-300mg DHA), (3% thymoquinone),(450mg anise seed) per day for one month.
In addition to the standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3/thymoquinone / Deglycyrrhizinated Licorice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients that will receive every 14-days Omega-3/thymoquinone supplementation (300-400mg EPA &amp; 200-300mg DHA), (3% thymoquinone),(Deglycyrrhizinated Licorice 800 mg ) per day for one month.
In addition to the standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The standard protocol care for COVID-19 approved from ministry of health at Saudi arabia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3/Nigella Sativa Oil</intervention_name>
    <description>Omega-3 supplementation 1000mg contains (300-400mg EPA &amp; 200-300mg DHA)
Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone</description>
    <arm_group_label>Omega-3/thymoquinone supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3/Nigella Sativa Oil/Indian Costus</intervention_name>
    <description>Omega-3 supplementation 1000mg contains (300-400mg EPA &amp; 200-300mg DHA)
Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Indian Costus supplements</description>
    <arm_group_label>Omega-3/thymoquinone / Indian Costus supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3/Nigella Sativa Oil/Quinine pills</intervention_name>
    <description>Omega-3 supplementation 1000mg contains (300-400mg EPA &amp; 200-300mg DHA)
Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Quinine supplementation (1g Quinine)</description>
    <arm_group_label>Omega-3/thymoquinone / Quinine pills</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3/Nigella Sativa Oil/Anise seed capsule</intervention_name>
    <description>Omega-3 supplementation 1000mg contains (300-400mg EPA &amp; 200-300mg DHA)
Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Anise seed supplementation (450mg anise seed)</description>
    <arm_group_label>Omega-3/thymoquinone / Anise seed capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice</intervention_name>
    <description>Omega-3 supplementation 1000mg contains (300-400mg EPA &amp; 200-300mg DHA)
Nigella sativa supplementation (1g black seed oil contain 3% thymoquinone
Deglycyrrhizinated Licorice 800 mg</description>
    <arm_group_label>Omega-3/thymoquinone / Deglycyrrhizinated Licorice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>Standard protocol care of COVID-19 infection</description>
    <arm_group_label>Active Comparator: standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic with respiratory or systemic symptoms

          -  Positive nasopharyngeal swab for COVID-19

          -  CT imaging showing viral pneumonia

          -  Temperature 38°C

          -  Respiratory rate &lt; 25 /min

          -  Oxygen saturation (pulse oximetry) &gt;95%

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Hepatic failure Child-Pugh C

          -  Negative swab test of (SARS)-(CoV-2)

          -  Expected life is less than 24 hours

          -  End-stage lung disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IVO IBRAHAM Prof of Pharmacy, Clinical Translational Sciences], Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>University of Arizona, College of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HASSAN Masmali [consultant of Pediatrics], M.D</last_name>
    <role>Study Director</role>
    <affiliation>Maternity and Children hospital,Mecca, Saudi Arabia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MOHAMED M ABDELWAHAB GAMALELDIN, Ph.D Candidate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SHAIMAA M Nashat SAYED ABDELHALIM, Ph.D Candidate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MOHAMED M ABDELWAHAB GAMALELDIN, Ph.D Candidate</last_name>
    <phone>00201110188554</phone>
    <email>dr.mohmedhat@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SHAIMAA M Nashat SAYED ABDELHALIM, Ph.D Candidate</last_name>
    <phone>00201110177667</phone>
    <email>drshimaa.nashat@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternity and Children hospital</name>
      <address>
        <city>Mecca</city>
        <state>Makkah</state>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOHAMED M ABDELWAHAB GAMALELDIN, Ph.D Candidate</last_name>
      <phone>00201110188554</phone>
      <email>dr.mohmedhat@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>SHAIMAA M NASHAT SAYED ABDELHALIM, Candidate</last_name>
      <phone>00201110177667</phone>
      <email>drshimaa.nashat@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>MOHAMED M ABDELWAHAB GAMALELDIN, Ph.D Candidate</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>SHAIMAA M NASHAT SAYED ABDELHALIM, Ph.D Candidate</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>HASSAN Masmali, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Mohamed Medhat Abdelwahab Gamaleldin</investigator_full_name>
    <investigator_title>Clinical researcher</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>omega3</keyword>
  <keyword>thymoquinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

